Lymph Node Examination for Stage I Second Primary Lung Cancer Patients Who Received Second Surgical Treatment
- 5 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 28 (3), 1810-1818
- https://doi.org/10.1245/s10434-020-08975-9
Abstract
Purpose This study aims to investigate the effect of lymph node examination on overall survival (OS) and lung cancer-specific survival (LCSS) in stage I second primary lung cancer (SPLC) patients who underwent second pulmonary resection. Patients and Methods We conducted a retrospective study with the Surveillance, Epidemiology, and End Results (SEER) database to identify stage I SPLC patients who received surgery from 1998 to 2015. The Kaplan–Meier method with landmark analysis and multivariable Cox regression analysis were performed to evaluate the prognostic value of lymph node examination. Results A total of 842 patients from the SEER database with stage I SPLC who underwent a second surgical treatment were included. The 5-year survival rate was 54.8% for the whole cohort. Multivariable analysis revealed that the number of lymph nodes examined (LNE) was associated with better OS and LCSS in SPLC patients after 12 months postoperatively. Patients with contralateral SPLC had significantly more nodes removed than those with ipsilateral SPLC. For contralateral SPLC, more than 10 LNE was correlated with improved long-term survival outcomes. Ipsilateral SPLC patients benefited from 4 or more LNE. However, the current analysis did not show a significant survival benefit from lymph node examination within 12 months after surgery. Conclusions For stage I SPLC patients who received surgical treatment after initial resection, an adequate number of LNE would improve both OS and LCSS. We recommend more than 10 LNE for contralateral SPLC and at least 4 LNE for ipsilateral SPLC.Keywords
Funding Information
- Shanghai Hospital Development Center (HDC12018122)
- Shanghai Municipal Health Commission (20174Y0111)
- Shanghai Science and Technology Committee (19XD1423200)
- National Natural Science Foundation of China (81972172)
This publication has 23 references indexed in Scilit:
- Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung CancerJournal of Thoracic Oncology, 2019
- Improved Lymph Node Staging in Early-Stage Lung Cancer in the National Cancer DatabaseThe Annals of Thoracic Surgery, 2017
- Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) DataJournal of Thoracic Oncology, 2017
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2013
- The Role of Surgical Treatment in Second Primary Lung CancerThe Annals of Thoracic Surgery, 2011
- Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung CancersJournal of Thoracic Oncology, 2010
- Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancerCancer, 2009
- Postoperative Survival and the Number of Lymph Nodes Sampled During Resection of Node-Negative Non-Small Cell Lung CancerSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2005
- Second Lung Cancers in Patients After Treatment for an Initial Lung CancerJNCI Journal of the National Cancer Institute, 1998